Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05889> ?p ?o ?g. }
Showing items 1 to 13 of
13
with 100 items per page.
- drugbank:DB05889 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05889 label "CMC-544 [drugbank:DB05889]" assertion.
- drugbank:DB05889 seeAlso DB05889 assertion.
- drugbank:DB05889 description "CMC544 is an antibody-cytotoxic conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia." assertion.
- drugbank:DB05889 identifier "drugbank:DB05889" assertion.
- drugbank:DB05889 title "CMC-544" assertion.
- drugbank:DB05889 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05889 drugbank_vocabulary:drugbank-id "DB05889" assertion.
- drugbank:DB05889 bio2rdf_vocabulary:x-identifiers.org DB05889 assertion.
- drugbank:DB05889 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05889" assertion.
- drugbank:DB05889 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05889 bio2rdf_vocabulary:identifier "DB05889" assertion.
- drugbank:DB05889 drugbank_vocabulary:x-wikipedia wikipedia:Inotuzumab_ozogamicin assertion.